Oxford Biomedica Solutions

oxford biomedica solutions, llc is the high-performing, full scope adeno-associated virus (aav) vector manufacturing and innovation joint venture of oxford biomedica plc (lse:oxb) (“oxford biomedica” or “the group”), and homology medicines, inc. (nasdaq: fixx) (“homology”). we offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in aav and lentiviral-based cell and gene therapies. oxford biomedica solutions llc provides access to homology’s innovative and proven end-to-end aav manufacturing capabilities, and customers also benefit from technical synergies brought in by the group’s know-how in lentiviral vector manufacturing. this collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.